Congo Ebola Outbreak Forces Wider Use of Merck Vaccine and Gilead Drug

The Democratic Republic of Congo's Ebola outbreak has worsened, prompting health officials to expand access to Merck & Co.'s Ebola vaccine and Gilead Sciences Inc.'s antiviral drug.

MORE THAN 4,000 CONFIRMED CASES AND 1,850 DEATHS HAVE BEEN REPORTED SINCE THE OUTBREAK WAS DECLARED 12 WEEKS AGO.

The Africa Centres for Disease Control and Prevention and Congolese officials plan to use the products across two provinces as conventional control measures are failing to contain the epidemic.